On Thursday, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) stock plunged after the company revealed disappointing data from the ...

"Repare Therapeutics’ individualised anaemia management trial shows promise" was originally created and published by Clinical ...

2024 年 10 月 9 日，德曲妥珠单抗获得国家药品监督管理局（NMPA）批准上市，用于治疗存在人表皮生长因子受体 ...

A poll of experts revealed that few are utilizing talquetamab for patients with pretreated relapsed/refractory myeloma.

An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 and RedirecTT-1 trials. Talquetamab, the bispecific GPRC5D-directed CD3 ...

根据 GLOBOCAN 2022 的最新数据，乳腺癌在全球范围内已成为女性癌症发病率与死亡率均居首位的疾病，其新发病例数量近 230 万例，而死亡病例则高达 67 ...

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with ...

BeiGene has seven presentations at IWWM 2024, and Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at ...

In the present study, also signs were improved including lower esophageal sphincter (LES) pressure (from 10 ± 1.58 and, 10.3 ± 1.68 mmHg in the pretreated patients to 16.5 ± 0.6, and 14.1 ± 0. ...

Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα ...

Preliminary safety and efficacy data from the phase 1 CaDAnCe-101 study demonstrates that BGB-16673 has a tolerable safety profile and shows promising antitumor activity in heavily pretreated ...